This cohort study examines the occurrence of diabetic retinopathy, ischemic optic nerve disease, or other ocular complications within 2 years of glucagon-like peptide-1 receptor agonist (GLP-1 RA) use among patients with type 2 diabetes. This evidence concerns the gene GLP1R and type 2 diabetes mellitus.